Introduction to Treating Patients with Buprenorphine for Primary Care Providers

12:00pm – 4:00pm

Click Here or Scan the QR code to Register

During May 2020–April 2021, the estimated number of drug overdose deaths in the United States exceeded 100,000 over a 12-month period for the first time. Medications for Opioid Use Disorder (MOUD), like Buprenorphine, methadone, and naltrexone have been proven to reduce overdose and death and providers that hold a DEA license with Schedule III Authority can prescribe Buprenorphine. Ensuring prescribers have the knowledge to initiate MOUD is imperative to helping patients with opioid use disorder. Q&A and discussion to follow.

Financial Incentive:

Primary Care Providers (Physicians and Advanced Practice Professionals) who attend this MOUD training are eligible to receive $250 incentive.

4 CME Credits Pending (4.0 hours)

• Meets DEA Training Requirements

Learning Objectives:

• Understand the basics of the neurobiology of addiction
• Understand the basic pharmacodynamics of buprenorphine
• Describe the diagnosis, intake, buprenorphine induction of a patient with OUD.
• Understand how to manage acute and chronic pain for patients with opioid use disorder with a specific emphasis on using buprenorphine for pain management
• Describe key principles in outpatient management of patients with OUD

Presenters:

• Sheba Sethi, MD
• Eliza Hutchinson, MD

Who should take this training:

• Physicians
• Nurse Practitioners
• Physician Assistants